Lithium is a widely used and highly effective treatment for mood disorders. However, a narrow therapeutic index, requiring routine monitoring of serum concentrations, is one of the clinical disadvantages. The first case of lithium-associated hyperparathyroidism (LAH) was reported in 1973. Longer duration of treatment is associated with increased incidence of LAH. 25% of patients on lithium have a thyroid or parathyroid abnormality, so regular monitoring of renal and endocrine function was recommended in a recent systematic review and meta-analysis. LAH is almost always caused by a single parathyroid adenoma. The treatment is parathyroid surgery. The aim of this study was to assess if calcium and parathyroid hormone levels are routinely checked in patients on lithium treamtmenttreatment.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Surgical Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2017 Published by Elsevier Inc.